IRS1 and hepatocellular carcinoma: Furthermore, miR-105 expression was found to be markedly downregulated in both HCC cell-lines and clinical HCC tissues and miR-105 could suppress the proliferation and tumorigenicity of HCC cells both in vitro and in vivo by deactivating the PI3K/AKT signaling pathway via targeting IRS1, AKT1 and PDK1, which suggests that miR-105 functions as a potential tumor suppressor [18].